Loading
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
Latest quote
¥2,927
+¥11.00 · +0.38%
Regular session · JST · Market data may be delayed.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
Day range
Current ¥2,927
52-week range
Current ¥2,927
Regular session · JST · Market data may be delayed.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
Day range
Current ¥2,927
52-week range
Current ¥2,927
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI EAFE ETFIEFA7.33M0.00%196.63B USD0.07%$99.42-1.06%
iShares MSCI EAFE Small-Cap ETFSCZ3.53M0.03%13.23B USD0.40%$86.07-0.88%
iShares Core MSCI Total International Stock ETFIXUS1.8M0.00%61.15B USD0.07%$97.57-0.76%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1.62M0.00%42.57B USD0.03%$51.60-0.92%
iShares Core MSCI International Developed Markets ETFIDEV1.25M0.00%32.93B USD0.04%$91.83-1.14%
State Street SPDR S&P International Small Cap ETFGWX374.15K0.04%942.7M USD0.40%$46.565-0.40%
iShares Core MSCI Pacific ETFIPAC341.12K0.01%2.85B USD0.09%$85.80-0.97%
iShares MSCI Japan Small-Cap ETFSCJ261.65K0.10%266.66M USD0.50%$110.06+0.07%iShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZiShares Core MSCI Total International Stock ETFIXUSState Street SPDR Portfolio Developed World ex-US ETFSPDWiShares Core MSCI International Developed Markets ETFIDEVState Street SPDR S&P International Small Cap ETFGWXiShares Core MSCI Pacific ETFIPACiShares MSCI Japan Small-Cap ETFSCJAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
